Compare · QTI vs TMDX
QTI vs TMDX
Side-by-side comparison of QT Imaging Holdings Inc. (QTI) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTI and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.50B, about 65.5x QTI ($38.1M).
- Over the past year, QTI is down 51.3% and TMDX is down 31.3% - TMDX leads by 20.0 points.
- TMDX has been more active in the news (5 items in the past 4 weeks vs 1 for QTI).
- TMDX has more recent analyst coverage (18 ratings vs 0 for QTI).
- Company
- QT Imaging Holdings Inc.
- TransMedics Group Inc.
- Price
- $2.91-4.59%
- $72.31+1.53%
- Market cap
- $38.1M
- $2.50B
- 1M return
- -23.42%
- -6.89%
- 1Y return
- -51.34%
- -31.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest QTI
- QT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations
- SEC Form DEF 14A filed by QT Imaging Holdings Inc.
- QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week
- A New Standard of Reproducibility for Quantitative Biomarkers in Breast Imaging
- SEC Form PRE 14A filed by QT Imaging Holdings Inc.
- QT Imaging Receives Saudi Arabia FDA Regulatory Clearance
- QT Imaging Set to Join the Russell Microcap® Index
- QT Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- QT Imaging Holdings Announces Closing of $10 Million Underwritten Public Offering
- SEC Form 424B5 filed by QT Imaging Holdings Inc.
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)